Welcome to our dedicated page for Celcuity news (Ticker: CELC), a resource for investors and traders seeking the latest updates and insights on Celcuity stock.
Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company headquartered in Minneapolis and focused on targeted therapies for oncology. News about Celcuity primarily centers on the development of its lead investigational drug, gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) pathway inhibitor being studied in multiple solid tumor indications, including HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer.
On this page, readers can follow Celcuity’s clinical trial milestones, such as topline and detailed results from the Phase 3 VIKTORIA-1 trial in HR+/HER2-/PIK3CA wild-type and mutant advanced breast cancer, as well as updates on the Phase 3 VIKTORIA-2 first-line trial and the Phase 1/2 CELC-G-201 study of gedatolisib plus darolutamide in mCRPC. Company press releases frequently report progression-free survival data, objective response rates, safety outcomes, and subgroup analyses from these studies.
Celcuity’s news flow also includes regulatory and corporate developments, such as the submission of a New Drug Application to the U.S. FDA for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer under the Real-Time Oncology Review program, participation in major medical meetings like the ESMO Congress and the San Antonio Breast Cancer Symposium, and presentations at healthcare investment conferences. In addition, the company announces financing transactions, including equity offerings, convertible senior notes, and amendments to its term loan facilities that support ongoing clinical and potential commercial activities.
Investors and healthcare professionals can use this news feed to monitor Celcuity’s latest disclosures on gedatolisib’s clinical performance, safety profile, regulatory progress, and capital strategy. Regular updates provide context on how the company’s oncology pipeline is advancing through late-stage development and regulatory review.
Celcuity Inc. (Nasdaq: CELC) has announced the release of its financial results for the third quarter of 2020 on November 9, 2020, after market close. A teleconference will follow at 4:30 p.m. ET to discuss these results. The company specializes in innovative cancer diagnostics through its CELsignia platform, which analyzes living tumor cells to identify new cancer sub-types that traditional diagnostics may miss. This advancement aims to improve patient outcomes and enhance targeted therapy definitions.
Celcuity Inc. (NASDAQ:CELC) will present at the LD 500 Investor Conference from September 1-4, 2020. CEO Brian Sullivan is scheduled to speak on September 2 at 11:00am ET on Track 1. The virtual presentation will be accessible via a live audio webcast, with an archived version available later. Celcuity focuses on developing next-generation diagnostics and therapeutic options for cancer patients through its innovative CELsignia platform. This conference provides a platform for one-on-one investor interactions to discuss the company's advancements.
Celcuity Inc. (NASDAQ:CELC) reported its second-quarter 2020 financial results, indicating a net loss of $2.20 million ($0.21 per share), up from $1.72 million ($0.17 per share) in Q2 2019. Operating expenses rose to $2.21 million, driven by increased R&D costs of $1.77 million. Cash and cash equivalents stood at $15.4 million as of June 30, 2020, expected to fund operations through 2021. The company remains focused on advancing its CELsignia diagnostic tests and anticipates announcing new collaborations by year-end, despite COVID-19-related delays in clinical trials.
Celcuity Inc. (NASDAQ:CELC) reported its second-quarter financial results for 2020, highlighting a net loss of $2.20 million, or $0.21 per share. Operating expenses rose to $2.21 million, driven by increased R&D costs of $1.77 million. Despite a cash burn rate remaining steady, cash and cash equivalents stood at $15.4 million as of June 30, expected to support operations through 2021. The company announced ongoing development of CELsignia tests and anticipates finalizing collaborations with pharmaceutical companies by year-end. Interim results from ongoing trials are expected in late 2021.